Anavex life sciences to participate in the btig virtual biotechnology conference 2021

New york, aug. 04, 2021 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) disorders, today announced that christopher u. missling, phd, president and chief executive officer of anavex, will participate in a fireside chat in the btig virtual biotechnology conference 2021 on tuesday, august 10, 2021 at 9:30 a.m. edt.
AVXL Ratings Summary
AVXL Quant Ranking